FCM
MYGN icon

Frontier Capital Management’s Myriad Genetics MYGN Stock Holding History

Frontier Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-613,594
Closed -$16.7M – 286
2019
Q4 		$16.7M Sell
613,594
-1,242,368
-67% -$34.2M 0.12% 187
2019
Q3 		$53.1M Sell
1,855,962
-1,221,222
-40% -$35.6M 0.42% 88
2019
Q2 		$85.5M Sell
3,077,184
-286,786
-9% -$8.1M 0.64% 46
2019
Q1 		$112M Buy
3,363,970
+140,404
+4% +$4.27M 0.79% 27
2018
Q4 		$93.7M Buy
3,223,566
+647,812
+25% +$23.3M 0.76% 35
2018
Q3 		$118M Buy
2,575,754
+198,819
+8% +$8.84M 0.76% 34
2018
Q2 		$88.8M Buy
2,376,935
+362,821
+18% +$12.3M 0.63% 47
2018
Q1 		$59.5M Buy
2,014,114
+58,247
+3% +$1.97M 0.43% 88
2017
Q4 		$67.2M Sell
1,955,867
-729,866
-27% -$24.6M 0.49% 78
2017
Q3 		$97.2M Sell
2,685,733
-347,655
-11% -$9.92M 0.7% 37
2017
Q2 		$78.4M Sell
3,033,388
-42,566
-1% -$904K 0.57% 60
2017
Q1 		$59.1M Buy
3,075,954
+41,432
+1% +$734K 0.44% 88
2016
Q4 		$50.6M Buy
3,034,522
+606,897
+25% +$11M 0.39% 94
2016
Q3 		$50M Buy
2,427,625
+596,597
+33% +$15.1M 0.4% 90
2016
Q2 		$56M Sell
1,831,028
-262,429
-13% -$9.12M 0.46% 75
2016
Q1 		$78.4M Buy
2,093,457
+95,716
+5% +$3.61M 0.62% 56
2015
Q4 		$86.2M Buy
1,997,741
+367,479
+23% +$15.5M 0.71% 38
2015
Q3 		$61.1M Buy
1,630,262
+494,256
+44% +$17.5M 0.51% 62
2015
Q2 		$38.6M Buy
1,136,006
+52,894
+5% +$1.8M 0.28% 133
2015
Q1 		$38.3M Buy
1,083,112
+73,694
+7% +$2.64M 0.28% 137
2014
Q4 		$34.4M Sell
1,009,418
-22,383
-2% -$794K 0.25% 142
2014
Q3 		$39.8M Buy
1,031,801
+1,531
+0.1% +$57.1K 0.32% 119
2014
Q2 		$40.1M Buy
1,030,270
+52,165
+5% +$1.94M 0.3% 129
2014
Q1 		$33.4M Buy
978,105
+437,797
+81% +$13.6M 0.24% 152
2013
Q4 		$11.3M Sell
540,308
-6,890
-1% -$174K 0.08% 251
2013
Q3 		$12.9M Buy
547,198
+72,760
+15% +$2.07M 0.1% 237
2013
Q2 		$12.7M Buy
+474,438
New +$13.8M 0.11% 228

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Frontier Capital Management's MYGN Position: Q1 2020 in Review

Frontier Capital Management sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 613,594 shares — an estimated $16.7M sold.

Frontier Capital Management first reported a position in MYGN in Q2 2013 and held it in 27 quarters. The position peaked at $118M in Q3 2018. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

  • Frontier Capital Management reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
  • Frontier Capital Management sold 613,594 Myriad Genetics shares in Q1 2020, an estimated $16.7M.
  • Frontier Capital Management first reported a position in Myriad Genetics in Q2 2013 and held it in 27 quarters.
  • Frontier Capital Management's Myriad Genetics position peaked at $118M in Q3 2018.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Frontier Capital Management's 13F filing for Q1 2020, filed 16 Apr 2020.